HDV Translational Science

Hepatitis Delta virus (HDV) does not receive a lot of attention and there is much we still do not understand. HDV is referred to as a “satellite” virus because it is only infectious in the presence of the hepatitis B virus (HBV). This can occur in two ways: coinfection with both HDV and HBV at the same time or the HDV superinfection of an already HBV-infected individual. It is not known why HDV superinfection (compared to co-infection) leads to a higher risk of chronic HDV infection and hepatitis. There is no vaccine for HDV, but it can be theoretically controlled as a result of the success of global HBV vaccinations. In the US, there is an alarming trend in the rise of HDV cases. Hepatitis D remains a serious challenge for three reasons. First, there is no FDA approved therapy, and the current treatment with interferon-alpha has a very low success rate (<25%). It is the most aggressive form of viral hepatitis and results in accelerated liver-related deaths and hepatocellular carcinoma (a common form of liver cancer). Lastly, there are limited cell-culture and animal models to study the virus in order to test new antivirals. Dahari Lab works across disciplines with computational modelers, virologists, clinicians, mouse-model experts and pharmaceutical companies on advancements in treatment. Our focus is on the discovery of HDV treatment response dynamics, the optimization of HDV therapy, and the evaluation of anti-HDV mode of actions of new drugs. These areas are critical to success in early development as well as clinical trials.

 

 

 

 

 

Click here for the full extent of our lab's research!

Research Topics


Partnerships that get results: Global. Fluid. Connected. Join Us!

Loyola University Medical Center

Department of Medicine

Division of Hepatology

2160 S. First Ave
Mulcahy Center, Rm 1610

Maywood, IL 60153, USA

Email: hdahari@luc.edu

Phone: 708-216-4682

Fax: 708-216-6299